The masterbrain's trajectory (blue, curved through its 7 checkpoints), the deterministic v0.3 control (dashed), and the actual price (green) overlaid from the prediction date forward.
Forecast Change+13.3% to $54.50
Predicted High$54.50at 6 months
Predicted Low$47.00at 1 month
Max Drawdown (predicted)-2.3%
Forecast
The masterbrain trajectory — 7 dated checkpoints. Short rungs (2w, 1m) show the typical range as the primary claim; point calls run from 2 months out. Every claim still gets graded.
Predicted Aug 25, 2026 1:05 pm
Bull
NVO trends higher to
$54.50
(+13.3% from $48.12)
by Feb 2027.
dip-then-recover
ThesisNVO is caught between an attractive valuation gap (composite FV ~$57, DCF ~$64) and heavy sentiment overhang from Lilly competitive dread. Absent a near-term catalyst the tape drifts flat-to-lower first, then value gravity and a strong recent earnings track pull it toward the mid-50s over the back half of the window.
Invalidated ifA close below $44 sustained for a week, or a Lilly clinical/label shock that widens the GLP-1 gap, would falsify the recovery leg.
Checkpointtime after the call
Datewhen it gets graded
Predictedthe claim: closing price
Current priceactual close — fills in over time
Predicted returnpredicted vs $48.12 at call
Conv.brain's confidence, 1–10
Driverwhy the brain put the point here
Prediction made
Aug 25, 2026
—
$48.12at call
—
—
The anchor — every point below is measured from this price and date.
2 weeks
Sep 8, 2026
$44.45–$51.79typical range · internal point $47.60
—
±7.6%
6/10
Sentiment overhang dominates near term with no catalyst
What actually happened:
closed $46.60
on Sep 4, 2026 = -3.2% vs the call
(predicted -1.1%)
· direction HIT
(called flat, was flat)
· off by 2.1 pp
· accuracy 9/10
· typical range ±7.6%:
inside the band
· S&P +0.5%
over the same window — beat it
1 month
Sep 25, 2026
$42.81–$53.43typical range · internal point $47.00
—
±11.0%
6/10
Continued Lilly narrative pressure, low beta drift
What actually happened:
closed $38.62
on Sep 24, 2026 = -19.7% vs the call
(predicted -2.3%)
· direction MISS
(called flat, was down)
· off by 17.4 pp
· accuracy 4/10
· typical range ±11.0%:
OUTSIDE the band
· S&P +0.4%
over the same window — beat it
2 months
Oct 25, 2026
$48.50
—
+0.8%
5/10
Value buyers step in near attractive-below threshold
3 months
Nov 25, 2026
$50.80
—
+5.6%
5/10
Earnings season likely reaffirms GLP-1 growth
4 months
Dec 25, 2026
$52.50
—
+9.1%
4/10
Year-end mean reversion toward composite fair value
5 months
Jan 25, 2027
$53.80
—
+11.8%
4/10
Value gravity pulls toward baseline endpoint
6 months
Feb 25, 2027
$54.50
—
+13.3%
4/10
Converges near deterministic baseline, below signal FV
Why ranges on the short rungs?
A 102-prediction trial (2026-07-21) showed 2-week point calls carry no information here —
three prompt formulations all lost to simply predicting zero — while the stock's own
volatility scale (σ×√t) described those windows well. So the short rungs claim what's
actually knowable: the typical travel, with earnings timing flagged where the variance
will come from. The internal point calls keep being generated and graded to map where
real skill begins. Full evidence: stocks/predictions/V0.5-DESIGN.md §8.
Deterministic control (v0.3 value line) targets
$53.90
(+12.0%)
— both lines get graded at every checkpoint, so the brain has to beat the formula, not just replace it.
Brain: claude-opus-4-7.